Patents by Inventor Derek J. Norris

Derek J. Norris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • URACIL DERIVATIVES AS MER-AXL INHIBITORS
    Publication number: 20230339891
    Abstract: The invention relates generally to compounds that are Mer-Ax1 inhibitors, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Application
    Filed: May 2, 2019
    Publication date: October 26, 2023
    Inventors: Christine M. Tarby, Derek J. Norris, Julian C. Lo, Vijay T. Ahuja, Steven P. Seitz, Ashvinikumar V. Gavai, John S. Tokarski, Mohini Rajasagi, Michael Wichroski, Matthias Broekema
  • NLRP3 MODULATORS
    Publication number: 20220089571
    Abstract: The present invention provides compounds of Formula (I): Formula (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Application
    Filed: January 13, 2020
    Publication date: March 24, 2022
    Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Derek J. Norris, Hua Gong, Yong Zhang, Patrice Gill, Christine M. Tarby, Matthias Broekema, Scott Hunter Watterson
  • NLRP3 MODULATORS
    Publication number: 20220089572
    Abstract: The present invention provides compounds of Formula (I):(I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Application
    Filed: January 13, 2020
    Publication date: March 24, 2022
    Inventors: Ashvinikumar V. Gavai, Derek J. Norris, Daniel O'MALLEY, Steven P. Seitz, Jay A. Markwalder, David K. Williams, Hua Gong, Scott Hunter Watterson, Christine M. Tarby
  • CYCLIC PROTEIN TYROSINE KINASE INHIBITORS
    Publication number: 20190210986
    Abstract: Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
    Type: Application
    Filed: March 18, 2019
    Publication date: July 11, 2019
    Inventors: Jagabandhu Das, Ramesh Padmanabha, Ping Chen, Derek J. Norris, Arthur M.P. Doweyko, Joel C. Barrish, John Wityak
  • Tricyclic compounds as anticancer agents
    Patent number: 10112941
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: October 30, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Francis Y. Lee, John S. Tokarski
  • CYCLIC PROTEIN TYROSINE KINASE INHIBITORS
    Publication number: 20180016247
    Abstract: Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 18, 2018
    Inventors: Jagabandhu Das, Ramesh Padmanabha, Ping Chen, Derek J. Norris, Arthur M.P. Doweyko, Joel C. Barrish, John Wityak
  • NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS
    Publication number: 20170327498
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 16, 2017
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Francis Y. Lee, John S. Tokarski
  • Tricyclic compounds as anticancer agents
    Patent number: 9751879
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: September 5, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, Jr., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • Tricyclic compounds as anticancer agents
    Patent number: 9725449
    Abstract: The present invention is directed to tricyclic compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: August 8, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Derek J. Norris, Wayne Vaccaro, Mikkel V. DeBenedetto, Andrew P. Degnan, George V. Delucca, Jeffrey A. Deskus, Wen-Ching Han, Godwin Kwame Kumi, William D. Schmitz, John E. Starrett, Jr., Matthew D. Hill, Hong Huang
  • TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS
    Publication number: 20160333013
    Abstract: The present invention is directed to tricyclic compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: May 10, 2016
    Publication date: November 17, 2016
    Inventors: Derek J. Norris, Wayne Vaccaro, Mikkel V. DeBenedetto, Andrew P. Degnan, George V. Delucca, Jeffrey A. Deskus, Wen-Ching Han, Godwin Kwame Kumi, William D. Schmitz, John E. Starrett, JR., Matthew D. Hill, Hong Huang
  • Carbazole compounds useful as bromodomain inhibitors
    Patent number: 9492460
    Abstract: The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: November 15, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Poss, David R. Tortolani, Dharmpal S. Dodd, Christopher P. Mussari, John S. Tokarski, Ashvinikumar V. Gavai, Yufen Zhao, George V. Delucca, Daniel O'Malley, Derek J. Norris, Patrice Gill, Claude A. Quesnelle, Wen-Ching Han
  • NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS
    Publication number: 20160326173
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: July 26, 2016
    Publication date: November 10, 2016
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, JR., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS
    Publication number: 20160318928
    Abstract: The present invention is directed to tricyclic compounds (I), pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: December 23, 2014
    Publication date: November 3, 2016
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, JR., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • Tricyclic compounds as anticancer agents
    Patent number: 9458156
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: October 4, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Francis Y. Lee, John S. Tokarski
  • NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS
    Publication number: 20160176864
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: December 23, 2014
    Publication date: June 23, 2016
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, JR., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
    Patent number: 9242941
    Abstract: Disclosed are compounds of Formula (I) and/or salts thereof: (I) wherein: R1 is CH2CH2CF3; R2 is CH2(cyclopropyl), CH(CH3)(cyclopropyl), or CH2CH2CH3; R3 is H, CH3, or Rx; R4 is H or Ry; and Rx, Ry, Ra, Rb, Rc, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer. The compounds of Formula (I) also include prodrugs of the Notch inhibitor compounds.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: January 26, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, Yufen Zhao, Daniel O'Malley, Claude A. Quesnelle, Brian E. Fink, Derek J. Norris, Wen-Ching Han, George V. DeLucca
  • ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS
    Publication number: 20150239851
    Abstract: Disclosed are compounds of Formula (I) and/or salts thereof: (I) wherein: R1 is CH2CH2CF3; R2 is CH2(cyclopropyl), CH(CH3)(cyclopropyl), or CH2CH2CH3; R3 is H, CH3, or Rx; R4 is H or Ry; and Rx, Ry, Ra, Rb, Rc, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer. The compounds of Formula (I) also include prodrugs of the Notch inhibitor compounds.
    Type: Application
    Filed: September 20, 2013
    Publication date: August 27, 2015
    Applicant: BRISTOL-METERS SQUIBB COMPANY
    Inventors: Ashvinikumar V. Gavai, Yufen Zhao, Daniel O'Malley, Claude A. Quesnelle, Brian E. Fink, Derek J. Norris, Wen-Ching Han, George V. DeLucca
  • CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS
    Publication number: 20140256700
    Abstract: The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: February 26, 2014
    Publication date: September 11, 2014
    Inventors: Michael A. Poss, David R. Tortolani, Dharmpal S. Dodd, Christopher P. Mussari, John S. Tokarski, Ashvinikumar V. Gavai, Yufen Zhao, George V. Delucca, Daniel O'Malley, Derek J. Norris, Patrice Gill, Claude A. Quesnelle, Wen-Ching Han
  • Cyclic protein tyrosine kinase inhibitors
    Patent number: 8716323
    Abstract: Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: May 6, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jagabandhu Das, Ramesh Padmanabha, Ping Chen, Derek J. Norris, Arthur M. P. Doweyko, Joel C. Barrish, John Wityak
  • Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function
    Patent number: 8067582
    Abstract: Disclosed are fused heterocyclic compounds of Formula (I) or pharmaceutically-acceptable salts or stereoisomers thereof. Also disclosed are methods of using such compounds in the treatment of at least one androgen receptor-associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: November 29, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Derek J. Norris, Ashvinikumar V. Gavai, James Aaron Balog, Joel F. Austin, Weifang Shan, Yufen Zhao, Andrew James Nation, Wen-Ching Han